Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes.Diabetologia · 2010
   Trial
2. Submaximal exercise coronary artery flow increases in postmenopausal women without coronary artery disease after estrogen and atorvastatin.Menopause (New York, N.Y.)
   Trial
3. Effects of isoflavones on lipid and apolipoprotein levels in patients with type 2 diabetes in Heilongjiang Province in China.Journal of clinical biochemistry and nutrition · 2016
   Article
4. Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance.Cardiovascular diabetology · 2014
   Article
5. Relationship between serum cholesterol and indices of erythrocytes and platelets in the US population.Journal of lipid research · 2013
   Article
6. Evidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapy.AIDS (London, England) · 2013
   Article
7. The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk.Current atherosclerosis reports · 2011
   Review
8. Non-HDL Cholesterol and Evaluation of Cardiovascular Disease Risk.EJIFCC · 2010
   Article
9. Relationship of serum cholesterol levels to atopy in the US population.Allergy · 2010
   Article
10. Novel relationship of serum cholesterol with asthma and wheeze in the United States.The Journal of allergy and clinical immunology · 2009
    Article
11. Intensive statin therapy in India: Demonstrating efficacy and safety.Indian heart journal
    Article

Corrections and comments

• Comment on
  Lipoprotein particle concentrations may explain the absence of coronary protection in the women's health initiative hormone trials.2008

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as